

iwCLL guidelines for diagnosis, indications for treatment supportive management of CLL

Blood

131, 2745-2760

DOI: [10.1182/blood-2017-09-806398](https://doi.org/10.1182/blood-2017-09-806398)

Citation Report

#	ARTICLE	IF	CITATIONS
1	On the architecture of translational research designed to control chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2018, 2018, 1-8.	0.9	10
3	From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development. Frontiers in Immunology, 2018, 9, 2402.	2.2	1
4	<i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica, 2018, 103, 1956-1968.	1.7	94
5	Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. PLoS ONE, 2018, 13, e0208180.	1.1	4
6	Isotype Specific Assembly of B Cell Antigen Receptors and Synergism With Chemokine Receptor CXCR4. Frontiers in Immunology, 2018, 9, 2988.	2.2	11
7	Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 93.	2.8	63
8	Genomic Biomarkers in Pathogenesis and Clinical Care of Chronic Lymphocytic Leukemia. Advances in Molecular Pathology, 2018, 1, 51-64.	0.2	1
11	Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia. EBioMedicine, 2018, 36, 7-8.	2.7	1
12	On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy, 2018, 19, 1675-1684.	0.9	0
13	Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. Genes Chromosomes and Cancer, 2018, 57, 533-540.	1.5	18
14	The Genomic Landscape of Chronic Lymphocytic Leukaemia: Clinical Implications. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S112-S115.	0.2	1
15	Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia. EBioMedicine, 2018, 35, 222-232.	2.7	7
17	Evolution of CLL treatment " from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology, 2018, 15, 510-527.	12.5	114
18	Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell, 2018, 22, 951-959.e3.	5.2	120
19	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 737-742.	0.2	1
20	Bone Marrow Defects and Platelet Function: A Focus on MDS and CLL. Cancers, 2018, 10, 147.	1.7	13
21	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood, 2018, 132, 892-902.	0.6	83
22	Management of melanoma in patients with chronic lymphocytic leukemia. Leukemia Research, 2018, 71, 43-46.	0.4	17

#	ARTICLE	IF	CITATIONS
23	Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?. Expert Opinion on Pharmacotherapy, 2018, 19, 1171-1175.	0.9	4
24	Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?. Acta Haematologica, 2018, 140, 51-54.	0.7	17
25	Expression of BTK/p-BTK is different between CD5+ and CD5- B lymphocytes from Autoimmune Hemolytic Anemia/Evans syndromes. Hematology, 2019, 24, 588-595.	0.7	4
26	Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. BMC Cancer, 2019, 19, 809.	1.1	9
27	State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. , 2019, 7, 202.		48
28	Distinctive IGHV gene usage and stereotyped receptors in South American patients with chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 644-648.	0.8	5
29	Examination of clonal evolution in chronic lymphocytic leukemia. Medical Oncology, 2019, 36, 79.	1.2	11
30	Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. Cancer, 2019, 125, 3699-3705.	2.0	11
31	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2019, 6, e470-e479.	2.2	20
32	How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. Current Oncology Reports, 2019, 21, 74.	1.8	4
33	Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. Advances in Cell and Gene Therapy, 2019, 2, e51.	0.6	0
34	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood, 2019, 134, 1132-1143.	0.6	81
35	Updates on CAR T-cell therapy in B-cell malignancies. Immunological Reviews, 2019, 290, 39-59.	2.8	61
36	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 2019, 94, 1266-1287.	2.0	352
37	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2019, 381, 432-443.	13.9	545
38	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematology,the, 2019, 6, e366-e374.	2.2	49
39	Chronic lymphocytic leukaemia: from genetics to treatment. Nature Reviews Clinical Oncology, 2019, 16, 684-701.	12.5	154
40	Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood, 2019, 134, 641-644.	0.6	77

#	ARTICLE	IF	CITATIONS
41	How Have Prognostic Factors Changed with Novel Therapies?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S116-S118.	0.2	0
42	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. <i>Leukemia Research</i> , 2019, 87, 106233.	0.4	16
43	On the BALL to spot the best score able to predict overall survival in relapsed or refractory CLL. <i>Lancet Haematology</i> , 2019, 6, e343-e344.	2.2	1
44	PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. <i>PET Clinics</i> , 2019, 14, 405-410.	1.5	10
45	The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 2455.	2.2	4
46	Dual antibody immunohistochemistry: an efficient and sensitive tool for the detection of residual disease in chronic lymphocytic leukemia. <i>Journal of Hematopathology</i> , 2019, 12, 183-190.	0.2	0
47	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305
48	Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience. <i>Hematological Oncology</i> , 2019, 37, 641-643.	0.8	5
49	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <i>Frontiers in Oncology</i> , 2019, 9, 689.	1.3	41
50	Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. <i>Targeted Oncology</i> , 2019, 14, 551-561.	1.7	10
51	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Targeted Oncology</i> , 2019, 14, 493-504.	1.7	6
55	Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment. <i>Expert Review of Hematology</i> , 2019, 12, 89-98.	1.0	8
56	European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. <i>Leukemia</i> , 2019, 33, 1851-1867.	3.3	92
57	Highs and lows of minimal residual disease in CLL. <i>Blood</i> , 2019, 133, 386-388.	0.6	3
58	Another step forward in the 20-year history of <i>IGHV</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 219-221.	1.7	11
59	Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. <i>Leukemia</i> , 2019, 33, 1801-1805.	3.3	5
60	The combination of complex karyotype subtypes and <i>IGHV</i> mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019, 121, 150-156.	2.9	31
61	Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019, 11, 822.	1.7	5

#	ARTICLE	IF	CITATIONS
62	Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984469.	1.1	3
63	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). <i>American Journal of Hematology</i> , 2019, 94, 1002-1006.	2.0	5
64	EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia. <i>Epigenetics</i> , 2019, 14, 1125-1140.	1.3	24
65	When abdominal pain knocks the door: an unusual presentation of chronic lymphocytic leukemia. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz037.	0.2	3
66	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019, 570, 474-479.	13.7	86
67	SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 321-325.	0.2	1
68	Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. <i>Leukemia and Lymphoma</i> , 2019, 60, 2939-2945.	0.6	16
69	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2019, 8, 3131-3141.	1.3	10
70	Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status. <i>Blood Cancer Journal</i> , 2019, 9, 47.	2.8	6
71	Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 487-498.	1.8	9
72	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	3.2	61
73	Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update. <i>Hematologic Malignancies</i> , 2019, , 69-77.	0.2	0
74	Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience. <i>Leukemia Research</i> , 2019, 81, 75-81.	0.4	8
75	Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 302-309.	1.2	11
78	Intricacies of CLL cytogenetic complexity. <i>Blood</i> , 2019, 133, 1168-1170.	0.6	0
79	The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 97-104.	0.6	7
80	Chronic Lymphocytic Leukemia Presenting as a Subcortical Watershed Infarct. <i>Case Reports in Hematology</i> , 2019, 2019, 1-5.	0.3	1
81	Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 423-430.	0.2	28

#	ARTICLE	IF	CITATIONS
82	<p>The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma</p>. Blood and Lymphatic Cancer: Targets and Therapy, 2019, Volume 9, 9-17.	1.2	9
83	Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia. SAGE Open Medical Case Reports, 2019, 7, 2050313X1882391.	0.2	1
84	Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control. Scientific Reports, 2019, 9, 4155.	1.6	4
85	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	3.3	21
86	Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer, 2019, 125, 1432-1440.	2.0	68
87	Blockage of autophagic flux is associated with lymphocytosis and higher percentage of tumoral cells in chronic lymphocytic leukemia of B cells. Clinical and Translational Oncology, 2019, 21, 1280-1285.	1.2	2
88	Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. European Journal of Cancer, 2019, 109, 196-203.	1.3	9
89	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood, 2019, 133, 2056-2068.	0.6	14
90	Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas. Methods in Molecular Biology, 2019, 1956, 139-155.	0.4	17
91	Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies. Methods in Molecular Biology, 2019, 1956, 157-197.	0.4	8
92	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the postâ€<sc>BCR</sc> inhibitor setting: a <sc>UK</sc> wide analysis. British Journal of Haematology, 2019, 185, 656-669.	1.2	53
93	Treatment-naïve CLL: lessons from phase 2 and phase 3 clinical trials. Hematology American Society of Hematology Education Program, 2019, 2019, 476-481.	0.9	3
94	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica, 2019, 104, 2144-2154.	1.7	20
95	A rare manifestation of chronic lymphocytic leukaemia â€“ leukaemia cutis treated with ibrutinib. Palliative Medicine, 2019, 11, 180-183.	0.1	1
96	Obstructive sleep apnoea in a patient with chronic lymphocytic leukaemia. BMJ Case Reports, 2019, 12, e228763.	0.2	3
97	Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia. Blood Advances, 2019, 3, 1891-1896.	2.5	10
98	Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1â€“derived peptides overcomes drug resistance. Blood Advances, 2019, 3, 2920-2933.	2.5	11
99	Treatment-naïve CLL: lessons from phase 2 and phase 3 clinical trials. Blood, 2019, 134, 1796-1801.	0.6	9

#	ARTICLE	IF	CITATIONS
100	Analysis of the secondary structure of blood serum proteins from patients with multiple myeloma. <i>Journal of Physics: Conference Series</i> , 2019, 1400, 033007.	0.3	0
101	Descriptive Analysis of Dosing and Outcomes for Patients with Ibrutinib-Treated Relapsed or Refractory Chronic Lymphocytic Leukemia in a Canadian Centre. <i>Current Oncology</i> , 2019, 26, 610-617.	0.9	13
102	Targeted Therapy in Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 378-385.	1.0	29
103	Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience. <i>Advances in Hematology</i> , 2019, 2019, 1-5.	0.6	6
104	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019, 11, 1834.	1.7	32
105	Chronic Lymphocytic Leukemia: Rapidly Changing Treatment Landscape. , 2019, , .		0
106	Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 442-448.	1.0	4
107	Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. <i>Frontiers in Immunology</i> , 2019, 10, 2832.	2.2	34
108	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 418-427.	1.0	8
109	A Patient with Chronic Lymphocytic Leukemia with Pancreatic Involvement. <i>Case Reports in Hematology</i> , 2019, 2019, 1-3.	0.3	0
110	Emerging treatment options for patients with p53-pathway-deficient CLL. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989135.	1.1	14
111	DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. <i>Clinical Epigenetics</i> , 2019, 11, 177.	1.8	15
112	The evolving treatment landscape of chronic lymphocytic leukemia. <i>Current Opinion in Oncology</i> , 2019, 31, 568-573.	1.1	15
113	Relevance of Minimal Residual Disease in the Era of Targeted Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 410-417.	1.0	8
114	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , 2019, 11, 1939.	1.7	39
115	Refractory Autoimmune Cytopenias Treated With Venetoclax. <i>HemaSphere</i> , 2019, 3, e202.	1.2	10
116	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. <i>HemaSphere</i> , 2019, 3, e287.	1.2	33
117	CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. <i>Leukemia</i> , 2019, 33, 518-558.	3.3	15

#	ARTICLE	IF	CITATIONS
118	Deep targeted sequencing of <i>TP53</i> in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment. <i>Haematologica</i> , 2019, 104, 789-796.	1.7	25
119	Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. <i>Blood</i> , 2019, 133, 990-992.	0.6	7
120	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019, 133, 1205-1216.	0.6	164
121	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. <i>Haematologica</i> , 2019, 104, 797-804.	1.7	28
122	Unravelling the suboptimal response of <i>TP53</i> -mutated chronic lymphocytic leukaemia to ibrutinib. <i>British Journal of Haematology</i> , 2019, 184, 392-396.	1.2	9
123	Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. <i>Cancer</i> , 2019, 125, 135-143.	2.0	20
124	CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 143-148.	0.7	26
125	Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 41-47.	0.2	19
126	Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. <i>Leukemia</i> , 2019, 33, 662-670.	3.3	26
127	The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. <i>Hematology</i> , 2019, 24, 173-182.	0.7	16
128	The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1644-1649.	0.6	7
129	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	5.1	448
130	Atypical chronic lymphocytic leukemia: Brief historical overview and current usage of an equivocal concept. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e17-e19.	0.7	7
131	Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 478-480.	0.5	4
132	Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. <i>Journal of Geriatric Oncology</i> , 2020, 11, 19-23.	0.5	2
133	Genomic data in prognostic models—what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 652-660.	1.2	2
134	Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 269-274.	0.1	11
135	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. <i>Human Molecular Genetics</i> , 2020, 29, 70-79.	1.4	17

#	ARTICLE	IF	CITATIONS
136	MRI and PET/MRI in hematologic malignancies. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1325-1335.	1.9	28
137	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	1.3	10
138	Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow. <i>Bone Marrow Transplantation</i> , 2020, 55, 974-978.	1.3	0
139	PI3K-p110 β contributes to antibody responses by macrophages in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 451-461.	3.3	8
140	Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. <i>Modern Pathology</i> , 2020, 33, 344-353.	2.9	6
141	Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. <i>Leukemia and Lymphoma</i> , 2020, 61, 557-566.	0.6	20
142	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 174-183.e3.	0.2	21
143	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020, 95, E16-E18.	2.0	2
144	The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 1507-1515.	3.2	13
145	98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2020, 9, 999-1007.	1.3	8
146	IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. <i>Haematologica</i> , 2020, 105, 1621-1629.	1.7	21
147	Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 934-939.	0.6	3
148	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 502-508.	2.0	9
149	An update on: molecular genetics of high-risk chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 109-116.	1.0	7
150	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 31-38.	1.0	5
151	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	1.9	15
152	Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 1995.	2.2	3
153	Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). <i>HemaSphere</i> , 2020, 4, e473.	1.2	26

#	ARTICLE	IF	CITATIONS
154	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	0.8	141
155	Targeting p53 in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1239-1250.	1.5	20
156	From pathogenesis to personalized treatments of neuropathies in hematological malignancies. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 212-221.	1.4	7
157	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. <i>HemaSphere</i> , 2020, 4, .	1.2	2
158	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	0.5	8
159	Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. <i>Expert Review of Hematology</i> , 2020, 13, 871-883.	1.0	8
160	Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2020, 80, 1973-1980.	4.9	6
161	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. <i>Acta Haematologica</i> , 2021, 144, 365-379.	0.7	13
162	Chemotherapy-free frontline therapy for CLL: is it worth it?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 24-32.	0.9	12
163	Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 33-40.	0.9	9
164	Managing toxicities of Bruton tyrosine kinase inhibitors. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 336-345.	0.9	76
165	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 357-362.	0.9	22
166	Approaches for relapsed CLL after chemotherapy-free frontline regimens. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 10-17.	0.9	8
167	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. <i>American Journal of Hematology</i> , 2020, 95, 1361-1367.	2.0	20
168	The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 885-894.	1.0	2
169	Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2312.	1.0	2
170	Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up. <i>Frontiers in Oncology</i> , 2020, 10, 1272.	1.3	24
171	Treatment of Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 460-473.	13.9	157

#	ARTICLE	IF	CITATIONS
172	Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. <i>European Journal of Haematology</i> , 2020, 105, 646-654.	1.1	34
173	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353.	1.7	8
174	Relation of Neutrophil Gelatinase-Associated Lipocalin Overexpression to the Resistance to Apoptosis of Tumor B Cells in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 2124.	1.7	7
175	MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells. <i>Experimental Hematology</i> , 2020, 88, 68-82.e5.	0.2	8
176	Theoretical study on the interactions between ibrutinib and gold nanoparticles for being used as drug delivery in the chronic lymphocytic leukemia. <i>Journal of Molecular Liquids</i> , 2020, 316, 113878.	2.3	4
177	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 901-908.	1.2	17
178	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. <i>Frontiers in Oncology</i> , 2020, 10, 1439.	1.3	26
180	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect Â® CLL Registry. <i>EJHaem</i> , 2020, 1, 188-198.	0.4	2
181	Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 228.	3.5	15
182	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 329-342.	0.5	2
183	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 1039-1046.	1.0	3
184	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020, 1, 537-544.	0.4	2
185	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. <i>Blood Advances</i> , 2020, 4, 4508-4511.	2.5	15
186	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
187	Imaging of Skeletal Involvement in Hemolymphatic Disorders. <i>Current Radiology Reports</i> , 2020, 8, 1.	0.4	0
188	Prevalence, distribution and predictive value of <i>XPO1</i> mutation in a real-life chronic lymphocytic leukaemia cohort. <i>British Journal of Haematology</i> , 2020, 191, e90-e94.	1.2	3
189	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1188-1200.	5.1	208
190	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. <i>Biomarker Research</i> , 2020, 8, 40.	2.8	33

#	ARTICLE	IF	CITATIONS
191	14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 509-518.	0.7	11
192	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
193	A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E310-E313.	2.0	3
194	A reduced panel of eight genes (ATM , SF3B1 , NOTCH1 , BIRC3 , XPO1 , MYD88 , TNFAIP3 , and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2020, 43, 683-692.	0.7	3
195	Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 594841.	2.2	11
196	Haematological malignancies: a guide to novel therapies. <i>The Prescriber</i> , 2020, 31, 9-15.	0.1	1
197	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2020, 123, 240-251.	2.9	13
198	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 2810-2818.	3.2	46
199	Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 254-260.	1.2	11
200	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	0.6	222
201	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. <i>Leukemia</i> , 2020, 34, 1979-1983.	3.3	4
202	Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. <i>Pharmacoeconomics</i> , 2020, 38, 941-951.	1.7	11
203	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 130-137.	0.3	3
204	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20
205	Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
206	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	0.6	83
207	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
208	A predictive tool for early-stage CLL. <i>Blood</i> , 2020, 135, 1820-1821.	0.6	4

#	ARTICLE	IF	CITATIONS
209	Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 168-176.	1.2	4
210	Cytogenetics in the genomic era. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101196.	0.7	5
211	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. <i>Blood</i> , 2020, 136, 1632-1644.	0.6	119
212	FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 421-428.	0.7	9
213	Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. <i>Leukemia</i> , 2020, 34, 2545-2551.	3.3	29
214	Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. <i>Current Treatment Options in Oncology</i> , 2020, 21, 24.	1.3	40
215	Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. <i>Current Oncology Reports</i> , 2020, 22, 36.	1.8	23
216	Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 1636-1644.	0.6	1
217	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. <i>Non-coding RNA</i> , 2020, 6, 11.	1.3	11
218	Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. <i>Leukemia and Lymphoma</i> , 2020, 61, 1627-1635.	0.6	11
219	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 438-444.e1.	0.2	18
220	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	3.2	80
221	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. <i>International Journal of Cancer</i> , 2020, 147, 1979-1986.	2.3	6
222	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	1.7	5
223	Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets. <i>Cancers</i> , 2020, 12, 629.	1.7	6
224	Precision Medicine Management of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 642.	1.7	28
225	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	1.7	8
226	Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature. <i>Leukemia Research Reports</i> , 2020, 14, 100200.	0.2	1

#	ARTICLE	IF	CITATIONS
227	Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1114-1125.	1.2	19
228	Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 612.	1.1	72
229	The dual PI3K \hat{I} /CK1 \hat{I} inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. <i>Blood Advances</i> , 2020, 4, 3072-3084.	2.5	52
230	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
231	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. <i>Cancer Immunology Research</i> , 2020, 8, 984-989.	1.6	7
232	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. <i>Haematologica</i> , 2020, 105, 2205-2217.	1.7	47
233	Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1435-1444.	0.6	15
234	Frontline treatment with the combination obinutuzumab $\hat{+}$ chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	2.0	12
235	Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada. <i>Leukemia Research</i> , 2020, 91, 106335.	0.4	10
236	Is There a Role for Chemotherapy in the Era of Targeted Therapies?. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 72-82.	1.2	3
237	Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. <i>British Journal of Haematology</i> , 2020, 189, 475-488.	1.2	13
238	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2020, 105, 2598-2607.	1.7	44
239	B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making. <i>Frontiers in Oncology</i> , 2020, 10, 67.	1.3	26
240	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. <i>Leukemia</i> , 2020, 34, 2038-2050.	3.3	38
241	CovCopCan: An efficient tool to detect Copy Number Variation from amplicon sequencing data in inherited diseases and cancer. <i>PLoS Computational Biology</i> , 2020, 16, e1007503.	1.5	20
243	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.4	5
244	Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 149-177.	9.6	17
245	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. <i>Nature Communications</i> , 2020, 11, 363.	5.8	75

#	ARTICLE	IF	CITATIONS
246	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. <i>Cancers</i> , 2020, 12, 282.	1.7	22
247	Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival. <i>Leukemia and Lymphoma</i> , 2020, 61, 1512-1515.	0.6	9
248	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	1.7	31
249	Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. <i>American Journal of Hematology</i> , 2020, 95, E108-E110.	2.0	8
250	Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 25-35.	1.0	12
251	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
252	Pregnancy in a 31-year-old woman with chronic lymphocytic leukemia: a case report and review of the literature. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 368-370.	0.1	2
253	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	0.6	33
254	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020, 12, 894.	1.7	22
256	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. <i>International Journal of Hematology</i> , 2020, 111, 642-656.	0.7	1
257	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
259	A drug potency signature links progression of chronic lymphocytic leukemia to mitochondria-related stress responses and metabolic reprogramming under hypoxia. <i>Toxicology and Applied Pharmacology</i> , 2020, 398, 115016.	1.3	1
260	How I manage CLL with venetoclax-based treatments. <i>Blood</i> , 2020, 135, 1421-1427.	0.6	20
261	<i>Pneumocystis jirovecii</i> pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020, 4, 1458-1463.	2.5	28
262	Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 657-668.	0.7	5
263	A novel flow cytometry-based assay to measure compromised B cell receptor signaling as a prognostic factor in chronic lymphocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1851-1857.	1.5	3
264	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020, 4, 165-173.	2.5	34
265	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 320-329.	1.8	16

#	ARTICLE	IF	CITATIONS
266	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
267	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 548-555.e4.	0.2	10
268	Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. <i>Haematologica</i> , 2021, 106, 682-691.	1.7	10
269	Chronic Lymphocytic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a035220.	2.9	28
270	Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 1608-1615.	1.7	12
271	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021, 35, 737-746.	3.3	61
272	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.	1.7	12
273	Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. <i>British Journal of Haematology</i> , 2021, 192, 720-728.	1.2	17
274	In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome. <i>British Journal of Haematology</i> , 2021, 192, 1068-1072.	1.2	5
275	Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 424-432.	2.3	5
276	Minimal residual disease—a novel concept in uveal melanoma. <i>Eye</i> , 2021, 35, 702-704.	1.1	3
277	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. <i>Journal of Clinical Oncology</i> , 2021, 39, 576-585.	0.8	74
278	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	0.6	111
279	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 112-117.	0.6	5
280	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	0.6	72
281	Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. <i>Experimental Hematology</i> , 2021, 93, 14-24.	0.2	10
282	Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13421.	1.7	1
283	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 23-33.	0.6	265

#	ARTICLE	IF	CITATIONS
284	Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169. <i>Blood</i> , 2021, 137, 1895-1904.	0.6	21
285	Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition. <i>Journal of Clinical Oncology</i> , 2021, 39, 551-553.	0.8	4
286	Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment. <i>Blood</i> , 2021, 137, 2182-2195.	0.6	7
287	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	0.6	38
288	Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 313-317.	0.3	3
289	CD43 in the malignant flow cytometry laboratory in 2020. <i>Expert Review of Hematology</i> , 2021, 14, 123-136.	1.0	4
290	A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 408-415.	0.6	2
291	EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells. <i>Biochemical Pharmacology</i> , 2021, 183, 114352.	2.0	3
292	A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression. <i>British Journal of Haematology</i> , 2021, 192, e77-e81.	1.2	1
293	Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography. <i>Leukemia Research</i> , 2021, 100, 106488.	0.4	3
294	A story of a pimple: Newly diagnosed chronic lymphocytic leukemia in a basal cell carcinoma biopsy. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 192-194.	0.7	1
295	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 54-69.	2.6	16
296	Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience. <i>Patient</i> , 2021, 14, 75-87.	1.1	4
297	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1597-1609.	3.3	15
298	SIRP α Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients. <i>Frontiers in Immunology</i> , 2020, 11, 610523.	2.2	1
299	Minimal Residual Disease (MRD) in Indolent Lymphomas. <i>Hematologic Malignancies</i> , 2021, , 21-39.	0.2	0
300	Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. <i>MAbs</i> , 2021, 13, 1917484.	2.6	8
301	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. <i>Karger Kompass Onkologie</i> , 2021, 8, 59-69.	0.0	0

#	ARTICLE	IF	CITATIONS
302	The ClpP activator ONC2012 (TR031) inhibits BCL2 and B-cell receptor signaling in CLL. <i>EJHaem</i> , 2021, 2, 81-90.	0.4	4
303	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. <i>Annals of Hematology</i> , 2021, 100, 987-993.	0.8	23
304	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1066-1076.	0.6	3
305	Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib. <i>Internal Medicine</i> , 2021, 60, 3305-3308.	0.3	1
306	Treatment of Chronic Lymphocytic Leukemia. <i>Hematologic Malignancies</i> , 2021, , 195-206.	0.2	0
307	Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. <i>Acta Haematologica</i> , 2021, 144, 508-518.	0.7	30
308	Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?. <i>Haematologica</i> , 2020, 106, 7-9.	1.7	2
309	Chronic Lymphocytic Leukemia of the Aortic Valve: A Case Report. <i>Cureus</i> , 2021, 13, e12517.	0.2	2
310	The Calcitriol/Vitamin D Receptor System Regulates Key Immune Signaling Pathways in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 285.	1.7	3
311	Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR). <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 126-134.	0.3	1
312	Activation of Interferon Signaling in Chronic Lymphocytic Leukemia Cells Contributes to Apoptosis Resistance via a JAK-Src/STAT3/Mcl-1 Signaling Pathway. <i>Biomedicines</i> , 2021, 9, 188.	1.4	8
314	Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 227-233.	2.3	2
315	Nonovert disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2021, 39, 423-427.	0.8	4
316	Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 481-488.	1.1	5
317	Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL. <i>Leukemia and Lymphoma</i> , 2021, 62, 1674-1681.	0.6	4
318	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, , .	0.7	3
320	EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2021, 26, 242-249.	1.9	9
321	Smudge Cells in Chronic Lymphocytic Leukemia: Pathophysiology, Laboratory Considerations, and Clinical Significance. <i>Laboratory Medicine</i> , 2021, 52, 426-438.	0.8	5

#	ARTICLE	IF	CITATIONS
322	Aberrant Expression of TLR2, TLR7, TLR9, Splicing Variants of TLR4 and MYD88 in Chronic Lymphocytic Leukemia Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 867.	1.0	5
323	Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia. <i>Clinical and Translational Medicine</i> , 2021, 11, e304.	1.7	7
324	Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. <i>Leukemia</i> , 2021, 35, 2325-2331.	3.3	13
325	The contribution of CD200 to the diagnostic accuracy of Matutes score in the diagnosis of chronic lymphocytic leukemia in limited resources laboratories. <i>PLoS ONE</i> , 2021, 16, e0247491.	1.1	6
326	Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. <i>Uchenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova</i> , 2021, 27, 80-96.	0.0	1
327	Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. <i>Cancers</i> , 2021, 13, 1336.	1.7	20
328	Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2021, 156, 433-444.	0.4	5
329	Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage. <i>Molecular and Clinical Oncology</i> , 2021, 14, 100.	0.4	0
331	Blood cancer driver Musashi-2 as therapeutic target in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 982-983.	3.3	0
332	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1816-1827.	0.6	0
333	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. <i>Cell Reports</i> , 2021, 34, 108845.	2.9	3
334	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2022, 107, 593-603.	1.7	18
335	A Tissue Counterpart to Monoclonal B-Cell Lymphocytosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1544-1551.	1.2	4
336	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. <i>Journal of Personalized Medicine</i> , 2021, 11, 249.	1.1	6
337	Population PK/DPD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 220-228.	2.3	2
338	The Case Nephrotic syndrome in a patient with chronic lymphocytic leukemia. <i>Kidney International</i> , 2021, 99, 777-778.	2.6	3
339	Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. <i>Frontiers in Immunology</i> , 2021, 12, 662866.	2.2	11
340	Oral PI3K-Î³ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2109-2119.	1.0	9

#	ARTICLE	IF	CITATIONS
341	Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 27.	0.9	14
342	Current and future treatment strategies in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 69.	6.9	33
343	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021, 138, 149-159.	0.6	20
344	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	0.6	539
345	COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia: Report of Two Cases and Literature Review. <i>Research in Oncology</i> , 2021, .	0.2	0
346	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	0.6	16
347	BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 1766.	1.7	27
348	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. <i>Cancers</i> , 2021, 13, 1782.	1.7	10
349	Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada. <i>Leukemia Research</i> , 2021, 103, 106538.	0.4	1
350	Validation of the Alternative International Prognostic Score (AIPS): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the CLL1a-GISL protocol. <i>European Journal of Haematology</i> , 2021, 106, 831-835.	1.1	6
351	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2021, 5, e564.	1.2	15
352	Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 674492.	1.3	9
353	How I treat chronic lymphocytic leukemia after venetoclax. <i>Blood</i> , 2021, 138, 361-369.	0.6	13
354	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	1.3	17
355	Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 225-234.	0.7	1
356	The future of laboratory testing in chronic lymphocytic leukaemia. <i>Pathology</i> , 2021, 53, 377-384.	0.3	3
357	Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5536.	1.8	17
358	A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	5

#	ARTICLE	IF	CITATIONS
359	Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. <i>Biomarker Research</i> , 2021, 9, 37.	2.8	5
360	Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Na ⁺ ve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis. <i>Clinical Drug Investigation</i> , 2021, 41, 595-604.	1.1	6
361	Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Clinical Cancer Research</i> , 2021, 27, 4531-4538.	3.2	20
362	Current Treatment Options in CLL. <i>Cancers</i> , 2021, 13, 2468.	1.7	20
363	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021, 35, 3163-3175.	3.3	25
364	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. <i>Diagnostics</i> , 2021, 11, 853.	1.3	15
365	Low-burden <i>TP53</i> mutations in CLL: clinical impact and clonal evolution within the context of different treatment options. <i>Blood</i> , 2021, 138, 2670-2685.	0.6	29
366	Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. <i>Annals of Hematology</i> , 2021, 100, 1837-1847.	0.8	11
367	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	1.3	12
368	Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective. <i>EJHaem</i> , 2021, 2, 628-634.	0.4	1
369	Monoclonal Gammopathy of Renal Significance. <i>New England Journal of Medicine</i> , 2021, 384, 1931-1941.	13.9	71
370	Chronic lymphocytic leukaemia. <i>Medicine</i> , 2021, 49, 286-292.	0.2	0
371	The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia. <i>Cancer Management and Research</i> , 2021, Volume 13, 3663-3674.	0.9	2
372	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia. <i>Advances in Oncology</i> , 2021, 1, 249-262.	0.1	1
373	The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 2064.	1.0	5
374	Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. <i>Cancer Science</i> , 2021, 112, 2405-2415.	1.7	7
375	Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-na ⁺ ve chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2342-2351.	0.6	8
376	Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2800-2803.	0.6	1

#	ARTICLE	IF	CITATIONS
377	Targeting HIF-1 β Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , 2021, 13, 2883.	1.7	12
378	Durable remissions following combined targeted therapy in patients with CLL harboring <i>TP53</i> deletions and/or mutations. <i>Blood</i> , 2021, 138, 1805-1816.	0.6	7
379	Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1085-1090.	2.5	1
380	PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia. <i>Clinical and Translational Oncology</i> , 2021, 23, 2309-2322.	1.2	6
381	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <i>Cancers</i> , 2021, 13, 3134.	1.7	6
382	Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 <i>CLL14</i> trial. <i>American Journal of Hematology</i> , 2021, 96, 1112-1119.	2.0	5
383	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
384	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	3.2	23
385	To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e493-e496.	0.2	2
386	Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday. <i>Current Medical Science</i> , 2021, 41, 431-442.	0.7	3
387	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274.	3.3	4
388	Chronic lymphoid leukemia metastasis to the gallbladder as a focal mass: A case report. <i>Radiology Case Reports</i> , 2021, 16, 1477-1484.	0.2	1
389	Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2516.	1.0	0
390	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	0.6	40
391	IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load. <i>Haematologica</i> , 2022, 107, 877-886.	1.7	5
392	A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2021, 10, 4387-4396.	1.3	9
393	Optic Perineuritis Presenting as the Initial Manifestation of Central Nervous System Involvement in Rai Stage 0 Chronic Lymphocytic Leukemia. <i>Journal of Neuro-Ophthalmology</i> , 2021, Publish Ahead of Print, e187-e191.	0.4	1
394	An Updated Review of Chronic Lymphocytic Leukemia. <i>Korean Journal of Medicine</i> , 2021, 96, 195-208.	0.1	0

#	ARTICLE	IF	CITATIONS
395	The role of cytogenetic and molecular testing in the diagnostics and prognostication of chronic B-cell lymphocytic leukemia. <i>Diagnostyka Laboratoryjna i Wiadomości PTDL</i> , 2021, 56, 1-17.	0.0	0
397	Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 12926.	1.6	3
398	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	3.3	40
399	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
400	Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1569-1571.	0.6	2
401	Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. <i>Clinical Radiology</i> , 2021, 76, 789-800.	0.5	3
402	Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 627-636.	2.0	4
403	Autoimmune Cytopenia in CLL. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 286-296.	1.0	5
404	Proteomics and Drug Repurposing in CLL towards Precision Medicine. <i>Cancers</i> , 2021, 13, 3391.	1.7	3
405	Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 282-289.	0.3	3
406	Management of Chronic Lymphocytic Leukemia in Less-Resourced Countries. <i>Cancer Journal (Sudbury,)</i> Tj ETQq0 0,0 rgt /Oylock 10	1.0	2
407	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3856.	1.7	12
408	Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 108-112.	1.2	7
409	The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2372-2382.	0.6	35
410	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021, 5, 2879-2889.	2.5	16
411	Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. <i>BMC Cancer</i> , 2021, 21, 777.	1.1	3
412	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 320-327.	1.0	2
413	Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 698572.	1.3	4

#	ARTICLE	IF	CITATIONS
414	Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management. <i>Current Oncology Reports</i> , 2021, 23, 102.	1.8	5
415	Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies. <i>Paediatric Drugs</i> , 2021, 23, 445-455.	1.3	1
416	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	3.2	23
417	Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 625-634.	1.7	83
418	Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutationsâ€”NOTCH1, SF3B1, MYD88, BIRC3. <i>Journal of Clinical Medicine</i> , 2021, 10, 3735.	1.0	7
419	Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 827-845.	0.9	3
420	Prognostic and Predictive Implications of Cytogenetics and Genomics. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 703-713.	0.9	2
421	Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Brutonâ€™s Tyrosine Kinase Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 793-806.	0.9	1
422	Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data. <i>Turkish Journal of Haematology</i> , 2021, 38, 273-285.	0.2	2
423	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8996.	1.8	73
424	The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 558-563.	0.2	2
425	Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 485-493.	1.2	8
426	Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2810-2827.	0.6	16
427	LYmphoid NeXt-Generation Sequencing (LYNX) Panel. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 959-974.	1.2	11
428	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
429	CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 4239.	1.7	1
430	A survival mediation model with Bayesian model averaging. <i>Statistical Methods in Medical Research</i> , 2021, 30, 2413-2427.	0.7	4
431	Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151177.	0.7	1

#	ARTICLE	IF	CITATIONS
432	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America, 2021, 35, 775-791.	0.9	8
433	Drug interaction (51. New oral anticancer drugs in hematological malignancies and drug) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	0.0	0
434	High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia. Leukemia Research, 2021, 107, 106604.	0.4	6
435	The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2021, 35, 687-702.	0.9	3
436	Phase 1 clinical trial of the PI3K γ inhibitor YY-20394 in patients with B-cell hematological malignancies. Journal of Hematology and Oncology, 2021, 14, 130.	6.9	10
437	Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e985-e999.	0.2	13
438	Incidental Finding of Chronic Lymphocytic Leukemia After Podiatric Surgery: Case Report. Journal of Foot and Ankle Surgery, 2021, , .	0.5	0
439	The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 169-173.	0.2	3
440	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Current Opinion in Oncology, 2021, 33, 670-680.	1.1	6
441	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Blood, 2021, 138, 2727-2730.	0.6	9
442	Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib. BMJ Case Reports, 2021, 14, e245350.	0.2	5
443	A Different View for an Old Disease: NEDDylation and Other Ubiquitin-Like Post-Translational Modifications in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 729550.	1.3	4
444	Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective. Current Oncology, 2021, 28, 3825-3835.	0.9	1
445	Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discovery, 2022, 3, 5-15.	2.6	25
446	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2022, 61, 37-43.	1.5	10
447	Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 729106.	1.3	1
448	The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL. Leukemia and Lymphoma, 2021, 62, 1-4.	0.6	1
449	Old Prognostic Markers Still Have a Role in CLL Management. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S139-S141.	0.2	0

#	ARTICLE	IF	CITATIONS
450	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021, 5, 4054-4058.	2.5	39
451	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021, 13, 4582.	1.7	28
452	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1391-1402.	5.1	53
453	LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021, 110, 106706.	0.4	6
454	Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 194-204.	0.7	6
455	Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1289-1301.	0.6	2
456	Concurrent BK polyomavirus, adenovirus and cytomegalovirus infections in a patient treated for chronic lymphocytic leukaemia. <i>BMJ Case Reports</i> , 2021, 14, e235981.	0.2	1
457	Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a caseâ€“control study. <i>BMC Research Notes</i> , 2021, 14, 21.	0.6	5
458	The evolving role of Brutonâ€™s tyrosine kinase inhibitors in chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	1.1	13
459	Mature B-Cell Neoplasms. , 2021, , 339-359.		0
460	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. <i>Annals of Hematology</i> , 2021, 100, 825-830.	0.8	2
461	Venetoclax-failed monotherapy in B-lymphoproliferative neoplasms responded to combination of venetoclax with immunochemotherapy: A report of two cases. <i>Leukemia Research</i> , 2020, 94, 106373.	0.4	1
462	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	0.6	15
464	Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?. <i>British Journal of Haematology</i> , 2020, 189, 809-810.	1.2	6
465	External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. <i>British Journal of Haematology</i> , 2021, 193, 133-137.	1.2	4
466	Relevance of TP53 for CLL diagnostics. <i>Journal of Clinical Pathology</i> , 2019, 72, 343-346.	1.0	10
467	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020, 135, 2266-2270.	0.6	67
468	Relapsed disease and aspects of undetectable MRD and treatment discontinuation. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 482-489.	0.9	2

#	ARTICLE	IF	CITATIONS
469	Chronic Lymphocytic Leukemia Concomitant with COVID 19: A Case Report. American Journal of Case Reports, 2020, 21, e926062.	0.3	18
470	Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study. Journal of Hematology (Brossard, Quebec), 2020, 9, 55-61.	0.4	2
471	Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia. Aging, 2020, 12, 16083-16098.	1.4	8
472	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. Oncotarget, 2018, 9, 34398-34412.	0.8	11
473	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	1.7	43
474	A step ahead toward precision medicine for chronic lymphocytic leukemia. Haematologica, 2020, 105, 2352-2355.	1.7	3
475	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. Haematologica, 2021, 106, 2354-2363.	1.7	62
477	Measurable residual disease in the treatment of chronic lymphocytic leukemia. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 138-145.	0.3	6
478	Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Reports, 2020, 12, 8296.	0.3	2
479	Lumbar erector spine plane block for pain management in postherpetic neuralgia in a patient with chronic lymphocytic leukemia. Indian Journal of Palliative Care, 2020, 26, 134.	1.0	4
480	Mucosa-associated Lymphoid Tissue Lymphoma-mimicking Primary Gastrointestinal Small Lymphocytic Lymphoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2020, 75, 212-215.	0.2	2
481	Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression. Blood Research, 2020, 55, 131-138.	0.5	8
482	Recent advances in chronic lymphocytic leukemia therapy. Blood Research, 2020, 55, S72-S82.	0.5	4
483	Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts. Central-European Journal of Immunology, 2020, 45, 334-341.	0.4	4
484	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 185-217.	2.3	40
485	Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia. Case Reports in Hematology, 2021, 2021, 1-4.	0.3	3
486	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood, 2022, 139, 1794-1806.	0.6	66
487	Precision diagnostics in lymphomas – Recent developments and future directions. Seminars in Cancer Biology, 2022, 84, 170-183.	4.3	13

#	ARTICLE	IF	CITATIONS
488	Driving Out Chronic Lymphocytic Leukemia With CART Cells. Transplantation and Cellular Therapy, 2022, 28, 5-17.	0.6	4
489	BTK Inhibitors in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2021, 16, 422-432.	1.2	7
490	Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal—Results from a population-based cancer registry cohort study. PLoS ONE, 2021, 16, e0258423.	1.1	2
491	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. American Journal of Hematology, 2021, 96, 1679-1705.	2.0	150
492	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. Blood Advances, 2022, 6, 148-151.	2.5	15
493	The Hydrophathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. Frontiers in Oncology, 2021, 11, 723722.	1.3	0
494	Chronic Myeloid Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL). , 2017, , .		0
497	Initial Therapy of Chronic Lymphocytic Leukemia. Hematologic Malignancies, 2019, , 79-96.	0.2	2
499	Treatment of relapsed chronic lymphocytic leukemia. Onkologie (Czech Republic), 2019, 13, 107-110.	0.0	0
501	EFFICACY OF OLIGONUCLEOTIDE DSP30 IN COMBINATION WITH INTERLEUKIN-2 FOR THE DETECTION OF CHROMOSOMAL ABERRATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Gematologiya i Transfuziologiya, 2019, 64, 21-34.	0.1	2
502	Diagnosis and management of complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. Acta Haematologica Polonica, 2019, 50, 91-97.	0.1	1
504	Features of cytogenetic diagnosis of simultaneous chronic lymphocytic leukemia and myelodysplastic syndrome: clinical case report. Oncogematologiya, 2019, 14, 69-76.	0.1	0
505	Determination of ZAP70 expression as a prognostic marker of chronic lymphocytic leukemia. ScienceRise: Medical Science, 2019, .	0.0	0
506	Maintenance therapy for chronic lymphocytic leukaemia. The Cochrane Library, 0, , .	1.5	1
507	Comparative efficacy of chronic lymphocytic leukemia treatment with or without rituximab. Oncogematologiya, 2019, 14, 12-17.	0.1	0
508	A minimális reziduis betegség vizsgálata krónikus limfoid leukémiában. Transfusio, 2020, 53, 17-22.	0.0	0
509	Development of an algorithm for the identification of leukemic hematolymphoid neoplasms in Primary Care patients. Diagnosis, 2021, 8, 239-247.	1.2	0
510	A Case of Indolent Mucormycosis of the Sphenoid Sinus in a Patient with Chronic Lymphocytic Leukemia in Complete Remission State. Journal of Clinical Otolaryngology, 2020, 31, 78-82.	0.1	0

#	ARTICLE	IF	CITATIONS
511	Orphan receptor ROR1 for detection of minimal residual disease in chronic lymphocytic leukemia. Medical Alphabet, 2020, , 19-24.	0.0	0
512	Reply to Aron P. Kater <i>et al</i>.. Haematologica, 2020, 105, e384-e384.	1.7	1
513	Chronic leukaemias in the community. Australian Prescriber, 2020, 43, 126-130.	0.5	1
515	Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients. Annals of Hematology, 2022, 101, 341-348.	0.8	2
516	A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in E μ 1/4-TCL1 mice through the JNK/STAT4/p66Shc axis. Pharmacological Research, 2021, 174, 105965.	3.1	1
518	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. American Journal of Hematology, 2022, 97, 90-98.	2.0	13
519	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematological Oncology, 2022, 40, 129-159.	0.8	4
520	CCR7 in Blood Cancers – Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target. Frontiers in Oncology, 2021, 11, 736758.	1.3	8
521	Survival, Causes of Death, and the Prognostic Role of Comorbidities in Chronic Lymphocytic Leukemia in the pre-ibrutinib era. A Population Based Study. European Journal of Haematology, 2021, , .	1.1	3
522	Clinical Utility of Chromosomal Microarray in Establishing Clonality and High Risk Features in Patients with Richter Transformation. Cancer Genetics, 2021, 260-261, 18-22.	0.2	2
523	Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer Journal, 2021, 11, 174.	2.8	11
524	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. The Cochrane Library, 2021, 2021, .	1.5	0
525	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers, 2021, 13, 5418.	1.7	7
526	Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood Research, 2020, 55, 206-212.	0.5	6
527	MODERN APPROACHES TO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Siberian Journal of Oncology, 2020, 19, 106-118.	0.1	0
528	Tumor lysis syndrome in chronic lymphocytic leukemia: conventional treatment versus novel agents. Medicine (United States), 2020, 99, e23632.	0.4	1
529	Highlights: B-chronic lymphocytic leukemia. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 122-123.	0.3	0
530	Detection of Minimal Residual Disease. , 2020, , 701-711.		0

#	ARTICLE	IF	CITATIONS
531	Cytohistologic Features of Salivary Gland Lymphomas. <i>AJSP Review and Reports</i> , 2020, 25, 249-254.	0.0	1
532	Clinical Efficacy of Ibrutinib Monotherapy and CHOP in the Treatment of Chronic Lymphocytic Leukemia. <i>Advances in Clinical Medicine</i> , 2020, 10, 2819-2826.	0.0	0
533	Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia. <i>Medicinski Podmladak</i> , 2020, 71, 47-53.	0.2	0
534	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
535	Comparison of factors associated with leukemia and lymphoma mortality in Brazil. <i>Cadernos De Saude Publica</i> , 2020, 36, e00077119.	0.4	5
536	Dielectric spectroscopy of blood serum of patients with chronic lymphocytic leukemia. <i>AIP Conference Proceedings</i> , 2020, , .	0.3	2
537	Improving Outcomes for Patients With Chronic Lymphocytic Leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 312-315.	0.2	0
538	High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. <i>Blood</i> , 2022, 139, 1557-1563.	0.6	20
539	Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL). <i>Diagnostics</i> , 2021, 11, 2041.	1.3	2
540	Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin. <i>Frontiers in Oncology</i> , 2021, 11, 771454.	1.3	8
541	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
542	Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example. <i>HemaSphere</i> , 2020, 4, e425.	1.2	2
544	Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab. <i>Frontiers in Immunology</i> , 2020, 11, 584509.	2.2	9
548	Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 736-751.	0.2	1
549	Effects of Ibrutinib on biophysical parameters of platelet in patients with chronic lymphocytic leukaemia. <i>American Journal of Blood Research</i> , 2020, 10, 311-319.	0.6	2
550	Anti-globulin test positivity indicates advanced disease in Indian CLL patients. <i>American Journal of Blood Research</i> , 2021, 11, 157-162.	0.6	0
551	Role of cytogenetic abnormalities detected by fluorescence hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia. <i>Indian Journal of Medical Research</i> , 2021, 153, 475-483.	0.4	0
552	Impact of clinical staging and demographic data (age and sex) on response to treatment and survival of chronic lymphocytic leukemia patients in Kurdistan Region of Iraq. <i>Iraqi Journal of Hematology</i> , 2021, 10, 102.	0.0	2

#	ARTICLE	IF	CITATIONS
553	Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. <i>Frontiers in Oncology</i> , 2021, 11, 769612.	1.3	10
554	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen. <i>Current Oncology</i> , 2021, 28, 4611-4633.	0.9	4
555	Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review. <i>Cancers</i> , 2021, 13, 5804.	1.7	10
556	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. <i>Blood Advances</i> , 2021, , .	2.5	9
557	Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	1
558	The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 177-187.	0.6	40
559	Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. <i>Cancer Medicine</i> , 2021, 10, 8789-8798.	1.3	6
560	Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia. <i>Clinical Immunology Communications</i> , 2021, 1, 35-44.	0.5	0
561	A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 23137.	1.6	9
562	A novel differential diagnosis algorithm for chronic lymphocytic leukemia using immunophenotyping with flow cytometry. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, 176-181.	0.1	7
563	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. <i>Blood Research</i> , 2021, , .	0.5	3
564	Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center. <i>EJHaem</i> , 2022, 3, 291-300.	0.4	2
565	Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high-dose methylprednisolone, revisited. <i>Cancer Medicine</i> , 2021, 10, 8768.	1.3	3
566	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. <i>Blood</i> , 2022, 139, 678-685.	0.6	96
567	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	2.2	48
568	Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2021, 25, 687-696.	0.3	1
569	Ibrutinib as First-Line Therapy in High-Risk Chronic Lymphocytic Leukemia: Case Reports. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 488-495.	0.1	0
570	Role of cytogenetic abnormalities detected by fluorescence in situ hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia. <i>Indian Journal of Medical Research</i> , 2021, 153, 475.	0.4	1

#	ARTICLE	IF	CITATIONS
571	Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients. <i>Iraqi Journal of Hematology</i> , 2021, 10, 139.	0.0	0
572	The significance of Rai and Binet clinical staging on the survival of chronic lymphocytic leukemia patients in the Kurdistan region of Iraq. <i>Iraqi Journal of Hematology</i> , 2021, 10, 146.	0.0	1
573	The pattern of bone marrow involvement among chronic lymphocytic leukemia patients and its impact on the disease outcome in Kurdistan Region of Iraq. <i>Iraqi Journal of Hematology</i> , 2021, 10, 158.	0.0	0
574	Prediction of Treatment Efficacy in Relapsed Chronic Lymphocytic Leukemia. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 466-476.	0.1	0
575	Prognostic factors for the progression of chronic lymphocytic leukemia. <i>Problemy Zdorov'Ā i Ākologii</i> , 2020, , 28-34.	0.0	0
576	Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 736-751.	0.2	1
577	Mature Lymphoid Neoplasms. , 2020, , 245-282.		0
578	An Anomaly with Potential as a New Prognostic Marker in CLL with del(13q): Gain of 16p13.3. <i>Cytogenetic and Genome Research</i> , 2021, 161, 479-487.	0.6	1
579	CLL und SLL: Gute Zwischenergebnisse. , 0, , .		0
580	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. <i>Frontiers in Oncology</i> , 2021, 11, 780085.	1.3	4
581	Identification of CD105 (endoglin) as novel risk marker in CLL. <i>Annals of Hematology</i> , 2022, 101, 773-780.	0.8	4
582	Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. <i>European Journal of Haematology</i> , 2022, 108, 369-378.	1.1	5
583	Towards precision medicine in lymphoid malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 221-242.	2.7	9
585	Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia. <i>Seminars in Cancer Biology</i> , 2022, 84, 329-338.	4.3	4
586	Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations. <i>Molecular Medicine Reports</i> , 2022, 25, .	1.1	4
587	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	1.7	6
588	COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoral and cellular immunity. <i>British Journal of Haematology</i> , 2022, 197, 41-51.	1.2	32
589	The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. <i>Blood Advances</i> , 2022, 6, 2701-2706.	2.5	11

#	ARTICLE	IF	CITATIONS
590	Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 663.	1.7	4
591	CLL update 2022: A continuing evolution in care. <i>Blood Reviews</i> , 2022, 54, 100930.	2.8	24
592	CLL12: a positive answer to a poorly phrased question. <i>Blood</i> , 2022, 139, 151-152.	0.6	2
593	Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. <i>Annals of Hematology</i> , 2022, 101, 491-511.	0.8	23
594	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 828471.	1.3	19
595	Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics. <i>Hematological Oncology</i> , 2022, 40, 469-474.	0.8	4
596	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. <i>Cancers</i> , 2022, 14, 771.	1.7	35
597	Recurrent anemia in a patient with chronic lymphocytic leukemia. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 91-98.	0.6	0
598	Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2022, 12, 1811.	1.6	2
599	Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia. <i>BMC Cancer</i> , 2022, 22, 148.	1.1	3
600	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2022, 18, 755-769.	1.1	1
601	Synchronous oral squamous cell carcinoma and a lymphoproliferative disorder in an adult: a challenge in diagnosis and management. <i>BMJ Case Reports</i> , 2022, 15, e246641.	0.2	1
602	Marginal-Zone Lymphomas. <i>New England Journal of Medicine</i> , 2022, 386, 568-581.	13.9	53
603	Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study. <i>Chemotherapy</i> , 2022, 67, 91-95.	0.8	14
604	Complex karyotype in a younger patient with chronic lymphocytic leukemia. <i>Onkologie (Czech)</i> 2022, 15, e246641.	0.0	0
605	Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab. <i>Annals of Hematology</i> , 2022, 101, 1387-1392.	0.8	3
606	New frontiers in chronic lymphocytic leukemia on the way to curing the disease. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 3-3.	0.3	0
608	BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion. <i>Molecular Cancer</i> , 2022, 21, 59.	7.9	21

#	ARTICLE	IF	CITATIONS
609	Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review. <i>Expert Review of Hematology</i> , 2022, 15, 273-284.	1.0	2
610	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	13.9	87
611	Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i. <i>Blood Advances</i> , 2022, 6, 1365-1370.	2.5	3
612	Druggable Molecular Pathways in Chronic Lymphocytic Leukemia. <i>Life</i> , 2022, 12, 283.	1.1	2
613	Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 64.	3.5	14
614	Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. <i>HemaSphere</i> , 2022, 6, e707.	1.2	17
615	Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism. <i>Frontiers in Oncology</i> , 2022, 12, 788113.	1.3	18
617	Prescription of Blood Lymphocyte Immunophenotyping in the Diagnosis of Lymphoid Neoplasms in Older Adults. <i>Journal of Clinical Medicine</i> , 2022, 11, 1748.	1.0	1
618	Real-world management of targeted therapies in chronic lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210908.	0.5	2
619	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of <i>WNT5A</i> promoter and undetectable expression of <i>WNT5A</i> gene. <i>Epigenetics</i> , 2022, 17, 1628-1635.	1.3	3
620	Obinutuzumab (GA-101), ibrutinib, and venetoclax (G1V) frontline treatment for high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 1318-1329.	0.6	30
621	Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1566-1579.	0.6	11
622	CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1617-1623.	0.6	3
623	PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 1571.	1.7	17
624	Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
625	Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. <i>European Journal of Haematology</i> , 2022, 108, 469-485.	1.1	4
626	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. <i>Blood Advances</i> , 2022, 6, 1732-1740.	2.5	13
627	From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. <i>Cancers</i> , 2022, 14, 1562.	1.7	9

#	ARTICLE	IF	CITATIONS
628	Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens. Cellular and Molecular Life Sciences, 2022, 79, 171.	2.4	13
629	Emergence of Chronic Lymphocytic Leukemia During Admission for COVID-19: Cause or Coincidence?. Cureus, 2022, 14, e23470.	0.2	4
630	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	1.2	7
632	Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Current Oncology Reports, 2022, 24, 1003-1014.	1.8	5
633	Kronik lenfositik ilâsemide tedavi yaklaÅmlarÅ: GerÅsek yaÅam verisi. Mersin Åniversitesi SaÅylÅk Bilimleri Dergisi, 0, , 50-55.	0.2	0
634	MRD in CLL: some answers, many questions. Blood, 2021, 138, 2746-2747.	0.6	2
635	BTKi, venetoclax, obinutuzumab: what is the ideal combination?. Memo - Magazine of European Medical Oncology, 2022, 15, 49-52.	0.3	1
636	Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with <i>TP53</i> aberrations: a pooled analysis from four clinical trials. British Journal of Haematology, 2022, 196, 947-953.	1.2	28
637	Bcl2 inhibitor venetoclax +/Å Anti-CD20: what do deep remissions mean?. Memo - Magazine of European Medical Oncology, 2022, 15, 45-48.	0.3	1
638	Atypical Mycobacterium Abscessus Infection in Stable Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature. Cureus, 2021, 13, e20574.	0.2	0
639	Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. Statistics in Medicine, 2022, 41, 751-768.	0.8	3
640	Frontline treatment in CLL: the case for time-limited treatment. Hematology American Society of Hematology Education Program, 2021, 2021, 59-67.	0.9	5
641	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia. Frontiers in Oncology, 2021, 11, 771669.	1.3	1
642	Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. Journal of Clinical Medicine, 2021, 10, 5845.	1.0	7
643	IMMUNE CYTOPENIAS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (PECULIARITIES, PROGNOSTIC) Tj ET Og 0 0 0 rgBT /Overlo	0.0	0
644	Prognostic significance of microRNA 17-92 cluster expression in Egyptian chronic lymphocytic leukemia patients. Journal of the Egyptian National Cancer Institute, 2021, 33, 37.	0.6	5
645	Virtual Screening of Adenylate Kinase 3 Inhibitors Employing Pharmacophoric Model, Molecular Docking, and Molecular Dynamics Simulations as Potential Therapeutic Target in Chronic Lymphocytic Leukemia. Future Pharmacology, 2021, 1, 60-79.	0.6	0
646	Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. Leukemia and Lymphoma, 2022, 63, 1137-1143.	0.6	2

#	ARTICLE	IF	CITATIONS
647	A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. <i>Cancer Research Communications</i> , 2022, 2, 258-276.	0.7	0
648	Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients. <i>Diagnostics</i> , 2022, 12, 953.	1.3	0
649	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. <i>Advances in Therapy</i> , 2022, 39, 2831-2849.	1.3	5
651	Structure and prognostic significance of 13q14 deletion in chronic lymphocytic leukemia. <i>Gematologiya i Transfuziologiya</i> , 2022, 67, 75-89.	0.1	3
652	Long-term outcomes for ibrutinib+rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	0.6	93
661	Disease-modifying anti-asthmatic drugs. <i>Lancet, The</i> , 2022, 399, 1664-1668.	6.3	42
662	Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data. <i>Blood Advances</i> , 2022, 6, 3716-3728.	2.5	6
663	Lymphoepithelioma-Like Gastric Carcinoma and Gastric Involvement of Chronic Lymphocytic Leukemia: Two Rare Identities Coexisting in One Patient.. <i>Journal of Medical Cases</i> , 2022, 13, 36-39.	0.4	1
670	Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Human Pathology</i> , 2022, 125, 108-116.	1.1	1
671	Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia. <i>EJHaem</i> , 2022, 3, 698-706.	0.4	1
672	Activated CLL cells regulate IL-17-producing Th17 cells in miR155-dependent and outcome-specific manners. <i>JCI Insight</i> , 2022, 7, .	2.3	2
673	Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
674	Unusual complications in the management of <sc>chronic lymphocytic leukemia</sc>. <i>American Journal of Hematology</i> , 2022, , .	2.0	1
675	<i>TRAF3</i> alterations are frequent in del(13)(q14) chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. <i>American Journal of Hematology</i> , 2022, 97, 903-914.	2.0	3
676	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.2	1
677	Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study. <i>Current Oncology</i> , 2022, 29, 3242-3251.	0.9	1
678	Defining disease modification in myelofibrosis in the era of targeted therapy. <i>Cancer</i> , 2022, 128, 2420-2432.	2.0	24
679	<i>TP53</i>-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. <i>American Journal of Hematology</i> , 2022, 97, 1005-1012.	2.0	6

#	ARTICLE	IF	CITATIONS
680	ROR1: an orphan becomes apparent. <i>Blood</i> , 2022, 140, 1583-1591.	0.6	22
681	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. <i>Cancer Science</i> , 2022, 113, 2763-2777.	1.7	11
682	Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells. <i>Blood Advances</i> , 2022, 6, 4185-4195.	2.5	6
683	Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. <i>Clinical Cancer Research</i> , 2022, 28, 4203-4211.	3.2	9
684	Lymphocytosis and chronic lymphocytic leukaemia: investigation and management. <i>Clinical Medicine</i> , 2022, 22, 225-229.	0.8	2
685	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. <i>Leukemia</i> , 2022, 36, 1961-1968.	3.3	34
686	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> , 2022, 140, 839-850.	0.6	55
687	Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 588-595.	0.8	0
688	Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. <i>Diagnostics</i> , 2022, 12, 1305.	1.3	14
689	Immunoglobulin Gene Mutational Status Assessment by Next Generation Sequencing in Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2022, , 153-167.	0.4	5
690	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. <i>Blood Advances</i> , 2022, 6, 5494-5504.	2.5	3
691	Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients. <i>Cancers</i> , 2022, 14, 2729.	1.7	1
692	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. <i>Cells</i> , 2022, 11, 1812.	1.8	5
693	Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. <i>Advances in Therapy</i> , 2022, 39, 3292-3307.	1.3	5
694	Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1869-1884.	0.5	0
695	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
696	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
697	Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 818-828.	5.1	21

#	ARTICLE	IF	CITATIONS
698	A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3206.	1.0	3
699	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 1100-1104.	0.8	1
700	IGH Translocations in Chinese Patients With Chronic Lymphocytic Leukemia: Clinicopathologic Characteristics and Genetic Profile. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
702	Rapid progression to Richter's syndrome in patient with chronic lymphocytic leukemia and near-triploid karyotype. <i>Vojnosanitetski Pregled</i> , 2022, , 60-60.	0.1	0
703	Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia. <i>Onkologie (Czech Republic)</i> , 2022, 16, 151-154.	0.0	0
704	Chronic Lymphocytic Leukemia With Leptomeningeal Involvement Presenting as an Acute Encephalopathy. , 0, , 1-6.		0
705	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	2.5	22
706	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. <i>Leukemia and Lymphoma</i> , 2022, 63, 2276-2289.	0.6	3
707	Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, 62, 136-146.	0.3	3
708	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. <i>Leukemia</i> , 2022, 36, 2125-2128.	3.3	4
709	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. <i>Biomolecules</i> , 2022, 12, 901.	1.8	2
710	Monoclonal B-cell Lymphocytosis " a review of diagnostic criteria, biology, natural history, and clinical management. <i>Leukemia and Lymphoma</i> , 2022, 63, 2795-2806.	0.6	3
711	TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
712	Targeting metabolic reprogramming in chronic lymphocytic leukemia. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	12
713	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia</i> , 2022, 36, 2129-2131.	3.3	3
714	Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). <i>Cancers</i> , 2022, 14, 3376.	1.7	18
715	Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 199, 239-244.	1.2	9
716	MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. <i>Blood Advances</i> , 2022, 6, 5593-5612.	2.5	3

#	ARTICLE	IF	CITATIONS
717	Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
718	Low <scp>CD49d</scp> Expression in Newly Diagnosed Chronic Lymphocytic Leukaemia May be Associated with <scp>Highâ€Risk</scp> Features and Reduced <scp>Treatmentâ€™Freeâ€™Intervals</scp> .. <i>European Journal of Haematology</i> , 0, , .	1.1	1
719	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1031-1043.	5.1	76
720	High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 219, 114923.	1.4	5
721	Hematologic Malignancy: The Lymphomas. , 2023, , 529-554.		0
722	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 81-98.	1.2	3
723	Practical management of chronic lymphocytic leukemia with acalabrutinib. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	1
724	TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. <i>Cancers</i> , 2022, 14, 3715.	1.7	6
725	Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages. <i>Diagnostics</i> , 2022, 12, 1802.	1.3	0
726	An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following ibrutinib Discontinuation. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
727	Splenic Size and Volume Measurements in Patients with Chronic Lymphocytic Leukemia. <i>Academic Radiology</i> , 2022, , .	1.3	1
728	Increased risk of severe cutaneous adverse reactions when cladribine is used together with other medications with a propensity for skin reactions. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	1
730	Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting. <i>HemaSphere</i> , 2022, 6, e761.	1.2	7
731	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2765-2784.	0.6	1
732	Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. <i>Lancet Haematology,the</i> , 2022, 9, e745-e755.	2.2	3
733	Approved and emerging Brutonâ€™s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1545-1557.	0.9	3
734	Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. <i>Clinical Cancer Research</i> , 2022, 28, 3958-3964.	3.2	3
735	A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. <i>Blood Advances</i> , 0, , .	2.5	2

#	ARTICLE	IF	CITATIONS
736	The spectrum of subclonal <i>TP53</i> mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study. <i>Hematological Oncology</i> , 2022, 40, 962-975.	0.8	2
737	Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort. <i>Blood Advances</i> , 2023, 7, 525-528.	2.5	2
738	Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. <i>PLoS ONE</i> , 2022, 17, e0272367.	1.1	3
739	Progression and survival of MBL: a screening study of 10%139 individuals. <i>Blood</i> , 2022, 140, 1702-1709.	0.6	12
740	Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	4
741	CLL management in 2022: Indian settings. <i>Journal of Current Oncology</i> , 2022, 5, 58.	0.2	0
742	Chronic lymphocytic leukemia: Current approach to lab diagnosis. <i>Journal of Current Oncology</i> , 2022, 5, 39.	0.2	1
743	<i>Babesia microti</i> -induced fulminant sepsis in an immunocompromised host: A case report and the case-specific literature review. <i>Open Life Sciences</i> , 2022, 17, 1200-1207.	0.6	3
744	Chronic lymphocytic leukemia diagnosed during pregnancy - case report and review of literature. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2022, 150, 602-605.	0.1	0
745	Diagnostic Applications of Nuclear Medicine: Leukemias. , 2022, , 529-567.		0
746	Targeting CD38 in Neoplasms and Non-Cancer Diseases. <i>Cancers</i> , 2022, 14, 4169.	1.7	10
748	The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia. <i>Blood</i> , 2023, 141, 369-379.	0.6	4
749	Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?. <i>Leukemia</i> , 2022, 36, 2743-2747.	3.3	3
750	Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance. <i>Leukemia and Lymphoma</i> , 2022, 63, 3331-3339.	0.6	3
751	5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2022, , 106952.	0.4	0
752	Anti-tumor effect of berberine on chronic lymphocytic leukemia cells. , 2022, 39, .		1
754	Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	3
756	Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2023, 60, 83-100.	2.7	1

#	ARTICLE	IF	CITATIONS
757	Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome. <i>Cancers</i> , 2022, 14, 4659.	1.7	1
758	MAJIC: a phase III trial of acalabrutinib+venetoclax versus venetoclax+obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Future Oncology</i> , 2022, 18, 3689-3699.	1.1	7
759	Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
760	Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101373.	0.5	1
761	GSK3 β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	0
762	Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
763	COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study. <i>HemaSphere</i> , 2022, 6, e780.	1.2	1
764	Management of front line chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
765	FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL. <i>Clinical Hematology International</i> , 2022, 4, 65-74.	0.7	6
766	Detecting measurable residual disease beyond 10 ⁻⁴ by an IGHV leader-based NGS approach improves prognostic stratification in CLL. <i>Blood</i> , 2023, 141, 519-528.	0.6	10
767	Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma. <i>European Journal of Haematology</i> , 0, , .	1.1	2
768	BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	35
769	Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry. <i>Blood Advances</i> , 2023, 7, 4760-4764.	2.5	1
770	Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. <i>Blood</i> , 2022, 140, 2709-2721.	0.6	22
771	Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study. <i>PLoS ONE</i> , 2022, 17, e0270291.	1.1	1
772	Clinical significance of serum sCD23 and B-cell maturation antigen levels in patients with chronic lymphocytic leukemia. <i>Iraqi Journal of Hematology</i> , 2022, .	0.0	0
773	Flow cytometry as a fast, cost-effective tool to assess <i>IGHV</i> mutational status in CLL. <i>Blood Advances</i> , 2023, 7, 4701-4704.	2.5	1
774	Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 1279-1291.	1.2	24

#	ARTICLE	IF	CITATIONS
775	Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia. <i>Current Medical Research and Opinion</i> , 0, , 1-13.	0.9	0
776	Current insights into the regulation of programmed cell death by TP53 mutation in cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
777	CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. <i>Cancers</i> , 2022, 14, 4917.	1.7	3
779	Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL. <i>European Journal of Haematology</i> , 0, , .	1.1	11
781	Monoclonal Gammopathy of Renal Significance: A Molecular Middle Earth between Oncology, Nephrology, and Pathology. <i>Kidney Diseases (Basel, Switzerland)</i> , 0, , 1-12.	1.2	3
782	Methylation microarray-based detection of clinical copy-number aberrations in CLL benchmarked to standard FISH analysis. <i>Genomics</i> , 2022, 114, 110510.	1.3	1
784	Immunotherapy approaches for hematological cancers. <i>IScience</i> , 2022, 25, 105326.	1.9	9
785	Patterns and predictors of referral to the specialized chronic lymphocytic leukemia clinic in Manitoba, Canada. <i>Cancer Epidemiology</i> , 2022, 81, 102279.	0.8	0
786	Modern Approach to Prognostication and Therapy of Chronic Lymphocytic Leukemia. , 2022, , .		0
787	Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones. <i>Leukemia Research Reports</i> , 2022, 18, 100359.	0.2	1
788	Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity. <i>Oncogematologiya</i> , 2022, 17, 196-204.	0.1	0
789	Inferring parameters of cancer evolution in chronic lymphocytic leukemia. <i>PLoS Computational Biology</i> , 2022, 18, e1010677.	1.5	3
790	Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-15.	1.4	2
791	Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. <i>Nature Genetics</i> , 2022, 54, 1675-1689.	9.4	21
792	Bendamustine-Rituximab in Young CLL: Relevance in the Era of Small Molecule Inhibitors. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.3	0
793	Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). <i>International Journal of Molecular Sciences</i> , 2022, 23, 14255.	1.8	8
794	Expression profile of immunophenotypic marker molecules on B-lymphocytes in patients with chronic lymphocytic leukemia at the stages of immunochemotherapy. <i>South Russian Journal of Cancer</i> , 2022, 3, 49-57.	0.1	0
795	Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. <i>Cancers</i> , 2022, 14, 5787.	1.7	7

#	ARTICLE	IF	CITATIONS
796	Chronic lymphocytic leukemia treatment algorithm 2022. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	12
797	Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 6983.	1.0	1
798	The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	3
799	Prognostic correlation of <i>NOTCH1</i> and <i>SF3B1</i> mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients. <i>Cancer Reports</i> , 0, , .	0.6	2
800	Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies. <i>International Journal of Hematology</i> , 0, , .	0.7	0
801	Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
804	In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T cell inhibitory properties, contributing to immunosuppression. <i>European Journal of Haematology</i> , 0, , .	1.1	0
805	Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. <i>Leukemia</i> , 2023, 37, 339-347.	3.3	14
807	Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. <i>Leukemia and Lymphoma</i> , 2023, 64, 300-311.	0.6	0
808	Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study). <i>Haematologica</i> , 2023, 108, 1691-1696.	1.7	2
809	Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2023, 23, 787-803.	1.1	5
810	Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2023, 388, 319-332.	13.9	108
811	Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
812	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. <i>Leukemia</i> , 2023, 37, 18-34.	3.3	21
814	Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. <i>Drugs - Real World Outcomes</i> , 2023, 10, 11-22.	0.7	2
815	Diagnosis of chronic lymphocytic leukemia during Mohs micrographic surgery. <i>JAAD Case Reports</i> , 2023, 33, 1-3.	0.4	1
816	Prognostic Value of the miR-17-92 Cluster in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1705.	1.8	4
817	High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study. <i>Haematologica</i> , 0, , .	1.7	2

#	ARTICLE	IF	CITATIONS
818	Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. <i>Leukemia Research</i> , 2023, 125, 107016.	0.4	6
819	Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 1033-1045.	0.5	2
820	A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements. <i>Haematologica</i> , 2023, 108, 1313-1321.	1.7	2
821	The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review. <i>Leukemia and Lymphoma</i> , 2023, 64, 788-798.	0.6	1
822	Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	5
823	The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
824	Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2023, 7, 2496-2503.	2.5	3
825	Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution. <i>Cancers</i> , 2023, 15, 891.	1.7	0
826	Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. <i>Journal of Immunology Research</i> , 2023, 2023, 1-17.	0.9	0
827	A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. <i>Blood Advances</i> , 2023, 7, 2632-2642.	2.5	2
828	Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2651-2662.	1.9	3
829	Venetoclax rampâ€p strategies for <sc>chronic lymphocytic leukaemia</sc> in the <sc>United Kingdom</sc>: a real world multicentre retrospective study. <i>British Journal of Haematology</i> , 2023, 202, 48-53.	1.2	3
830	Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections. <i>Expert Review of Hematology</i> , 2023, 16, 267-276.	1.0	0
831	Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
832	Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop. <i>American Journal of Clinical Pathology</i> , 0, , .	0.4	0
833	Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions. <i>Leukemia Research</i> , 2023, 129, 107072.	0.4	1
834	Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R. <i>Value in Health Regional Issues</i> , 2023, 36, 10-17.	0.5	0
837	STEREOTYPED CASES IN UKRAINIAN COHORT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS DEPENDING ON THE IONIZING RADIATION EXPOSURE. <i>Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii</i> , 2022, 27, 307-323.	0.5	1

#	ARTICLE	IF	CITATIONS
838	Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. <i>Nature Communications</i> , 2023, 14, .	5.8	13
839	Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib. <i>Biochemical and Biophysical Research Communications</i> , 2023, 650, 96-102.	1.0	0
840	Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of MYD88 Mutations. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3177.	1.8	4
841	Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS). <i>Cancers</i> , 2023, 15, 1017.	1.7	1
842	<scp>PYK2</scp> is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 576-586.	1.6	2
843	miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance – An emphasis on the interaction of signaling pathways. <i>Pathology Research and Practice</i> , 2023, 243, 154363.	1.0	7
845	Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
846	SOHO State of the Art Updates and Next Questions Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 322-332.	0.2	3
847	Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study. <i>Medicina (Lithuania)</i> , 2023, 59, 324.	0.8	1
848	Next-CLL, a New Next-Generation Sequencing-Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 274-283.	1.2	0
849	Measurable residual disease in chronic lymphocytic leukemia. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
850	Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia. <i>BioDrugs</i> , 2023, 37, 219-233.	2.2	1
851	Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
852	Expert consensus on the management of chronic lymphocytic leukaemia in Asia. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2895-2907.	1.9	1
853	Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2023, 15, 1294.	1.7	5
854	Editorial: Biology and treatment of high-risk CLL. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
855	Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2023, 7, e840.	1.2	1
856	Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis. <i>Leukemia and Lymphoma</i> , 2023, 64, 884-888.	0.6	2

#	ARTICLE	IF	CITATIONS
857	The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia. <i>Clinical Hematology International</i> , 2023, 5, 92-100.	0.7	1
858	The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
859	Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 1772.	1.0	1
860	Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow. <i>Cytometry Part B - Clinical Cytometry</i> , 0, , .	0.7	1
861	Secondary involvement of gallbladder by acute lymphoblastic leukemia presenting clinically as cholecystitis in a young patient: a case report. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
862	COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group. <i>Annals of Hematology</i> , 2023, 102, 811-817.	0.8	2
863	Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor. <i>Journal of Molecular Diagnostics</i> , 2023, , .	1.2	0
864	Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain. <i>Haematologica</i> , 0, , .	1.7	2
865	Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia. <i>Diagnostics</i> , 2023, 13, 964.	1.3	4
866	Differential prognosis of single and multiple <i>TP53</i> abnormalities in high-count MBL and untreated CLL. <i>Blood Advances</i> , 2023, 7, 3169-3179.	2.5	2
867	PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 13, 1-12.	1.2	6
868	Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia. <i>Surgical Pathology Clinics</i> , 2023, , .	0.7	0
869	Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. <i>Journal of the American Heart Association</i> , 0, , .	1.6	0
870	Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2023, 201, 874-886.	1.2	2
871	Spontaneous Tumor Lysis Syndrome in a Patient With a Known History of Chronic Lymphocytic Leukemia Prior to Cytotoxic Chemotherapy. <i>Cureus</i> , 2023, , .	0.2	0
872	Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5802.	1.8	3
873	Diagnosis and Treatment of Chronic Lymphocytic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 918.	3.8	32
874	Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	7

#	ARTICLE	IF	CITATIONS
875	Relationships between Tâ€lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study. <i>European Journal of Haematology</i> , 2023, 110, 732-742.	1.1	0
876	Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 1996.	1.7	1
877	Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies. <i>EJHaem</i> , 2023, 4, 339-349.	0.4	0
878	CCL3 as possible negative prognostic factor in chronic lymphocytic leukemia.. <i>Acta Haematologica</i> , 0, , .	0.7	0
879	An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
880	In-vitro Modulation of mTOR-HIF-1Î± Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , .	0.3	0
881	Sequencing and combination of current <scp>smallâ€molecule</scp> inhibitors for chronic lymphocytic leukemia: Where is the evidence?. <i>European Journal of Haematology</i> , 2023, 111, 15-28.	1.1	0
882	OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: SINGLE CENTER EXPERIENCE. , 2023, 3, 15-26.		0
883	Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2023, 14, .	5.8	18
884	An Extremely Rare Case of Prostate and Bladder Wall Involvement of Chronic Lymphocytic Leukemia. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2023, 11, 232470962311681.	0.3	1
885	CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies. , 2023, 40, .		0
886	MNK Proteins as Therapeutic Targets in Leukemia. <i>OncoTargets and Therapy</i> , 0, Volume 16, 283-295.	1.0	0
887	Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia. <i>Clinical Hematology International</i> , 2023, 5, 107-111.	0.7	0
913	<i>Cancers hÃ©matologiques</i> . , 2023, , 221-228.		0
922	Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia. , 2024, , 247-261.		0
977	Transformation of Chronic Lymphocytic Leukemia into Acute Mixed Phenotype Leukemia Myeloid/T Neoplasm: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0
991	Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
993	Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
995	Case report: Acute kidney injury as the initial manifestation of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
1002	Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
1026	Minimale Resterkrankung bei indolenten Lymphomen. , 2023, , 23-43.		0
1027	Behandlung der chronischen lymphatischen Leukämie. , 2023, , 215-227.		0
1031	Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease. <i>Current Oncology Reports</i> , 2024, 26, 136-146.	1.8	0
1038	Myélome, lymphomes et autres hémopathies malignes. , 2023, , 634-641.		0